Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
NEW YORK, Dec. 03, 2015 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Valeant Pharmaceuticals International, Inc. (“Valeant Pharmaceuticals”) (NYSE:VRX) between February 23, 2015 and October 20, 2015.
You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the District of New Jersey. To get more information go to:
http://zlk.9nl.com/valeant-pharmaceuticals
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that during the Class Period, defendants made false and misleading statements and/or failed to disclose adverse information about the Company’s business and prospects, including that: (a) the Company was using a network of specialty mail-order pharmacies that it actually controlled to prop up sales of its high-priced drugs and to keep patients and their insurance companies from switching to less costly generic drugs; (b) that Valeant's undisclosed use of specialty pharmacies left it subject to increased regulatory risks; and (c) that without the use of the specialty pharmacies, Valeant’s financial performance and Class Period financial guidance would have been negatively impacted. As a result of these false and misleading statements and/or omissions, Valeant stock traded at artificially inflated prices during the Class Period, reaching over $260 per share.
If you suffered a loss in Valeant Pharmaceuticals you have until December 21, 2015 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
